{"organizations": [], "uuid": "e3fbb3aa7955be038b0eb22ed2d5837ac49d2d7c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cymabay-therapeutics-says-first-pr/brief-cymabay-therapeutics-says-first-primary-biliary-cholangitis-patients-have-been-successfully-enrolled-in-seladelpar-long-term-extension-study-idUSFWN1P30PL", "country": "US", "domain_rank": 408, "title": "BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.46, "site_type": "news", "published": "2018-01-08T21:08:00.000+02:00", "replies_count": 0, "uuid": "e3fbb3aa7955be038b0eb22ed2d5837ac49d2d7c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cymabay-therapeutics-says-first-pr/brief-cymabay-therapeutics-says-first-primary-biliary-cholangitis-patients-have-been-successfully-enrolled-in-seladelpar-long-term-extension-study-idUSFWN1P30PL", "ord_in_thread": 0, "title": "BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "seladelpar", "sentiment": "none"}], "organizations": [{"name": "cymabay therapeutics inc", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Cymabay Therapeutics Inc:\n* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:08:00.000+02:00", "crawled": "2018-01-09T17:15:33.004+02:00", "highlightTitle": ""}